Type 1 Diabetes Prevention, Screening, and Insulin Access

NICE-backed NHS reimbursement for teplizumab could delay progression from stage 2 to stage 3 type 1 diabetes, while family-history screening may identify autoimmune disease before dangerous symptomatic onset. Implementation questions include eligibility, screening pathways, infusion capacity, adverse effects, durability, cost, and continuity of insulin coverage.